Table 2.

RESEARCH AND CLINICAL DIRECTIONS FOR P4 MEDICINE IN OSA

• Confirming clinical subgroups and relevance to outcomes.

• Developing personalized approaches to therapy based on clinical subgroups.

• Application of all OMIC approaches to identify molecular signatures that will provide prognostic information.

• Elucidating the genetic variants that confer risk or protection for OSA.

• Enhancing clinical phenotypes based on new physiological approaches and applying these in routine care.

• Understanding the reasons why some patients with OSA develop hypertension, CV disease, diabetes, etc. why others do not.

• Evaluating whether treatment of OSA can affect the rate of progression of neurodegenerative disease and in which types of patients.

• Development of mobile approaches for diagnosis and follow-up management of OSA.

• Enhanced prediction tools based on information from several domains—obesity measure, symptoms, facial photography, etc.

• Developing approaches to prevent OSA in individuals with upper airway compromise before they develop clinical disease.

• Developing personalized approaches to therapy.

• Understanding basis of different response to intra-oral devices and hypoglossal nerve stimulation.

• Widespread participatory care for patients with OSA based on new technologies.